Abstract
Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.
Copyright © 2010 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / adverse effects*
-
Angiogenesis Inhibitors / pharmacology*
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Humans
-
Kidney Glomerulus / drug effects
-
Kidney Glomerulus / pathology
-
Kidney Glomerulus / physiopathology
-
Mice
-
Models, Animal
-
Proteinuria / chemically induced*
-
Proteinuria / epidemiology
-
Proteinuria / pathology
-
Proteinuria / therapy
-
Renal Insufficiency / chemically induced*
-
Renal Insufficiency / epidemiology
-
Renal Insufficiency / pathology
-
Renal Insufficiency / therapy
-
Signal Transduction / genetics
-
Thrombotic Microangiopathies / chemically induced*
-
Thrombotic Microangiopathies / pathology
-
Thrombotic Microangiopathies / physiopathology
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / drug effects
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Vascular Endothelial Growth Factor A